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Abstract
Liver cirrhosis is irreversible and mostly ends up with complete loss of liver function/
end‐stage liver failure, and the only proven treatment is liver transplantation. Scarcity of 
donor, high cost, lifelong immunosuppression, and surgical complications are the major 
issues associated with liver transplantation and these urge to look for alternate therapeu‐
tic approaches. Advancements in the field of regenerative medicine are arising hope for 
the treatment of liver cirrhosis. This chapter deals with the scope of liver regenerative 
medicine in the treatment of liver cirrhosis. Review of the literature showed that liver 
regenerative medicine no doubt holds great promises and added a lot of hope to the cure 
of liver diseases. Primarily, cell‐based therapies had shown great potential to treat liver 
cirrhosis. Successful clinical human trials further strengthen their significance in the field. 
However, recent trends in liver regenerative medicine are focusing on the development 
of tissue engineering leading to generation of the whole organ. Despite advantages, liver 
regenerative medicine has several limitations and sometimes been over‐optimistically 
interpreted. In conclusion, the current scenario advocates to conduct more preclinical 
and clinical trials to effectively replace liver transplantation with liver regenerative medi‐
cine to treat liver diseases.
Keywords: regenerative medicine, stem cells, hepatocytes, tissue engineering
1. Introduction
Liver is one of the largest and most important metabolic organs in the human body with 
considerable regeneration capacity. However, in prolonged hepatic injuries, the regeneration 
capacity of hepatocytes times out and a cascade of life‐threatening complications is initiated 
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leading to liver cirrhosis. Liver cirrhosis is irreversible and mostly ends up with complete 
loss of liver function/end‐stage liver failure. End‐stage liver failure with high rates of morbid‐
ity and mortality poses a significant threat to human health as well as economy throughout 
the world [1]. As current pharmacological treatments are inefficient to reverse this loss, liver 
transplantation is the only effective lifesaving option. Since the first liver transplantation in 
1963, the number of cases requiring transplantation are considerably increasing with the pas‐
sage of time. Despite the success of liver transplantation, there is a gap between demand 
and supply. Only 30–50% of annual liver donation desires are fulfilled and at least about 
15% patients die while being on the waiting list [2, 3]. Besides scarcity of liver donors, high 
cost, postoperative graft rejection, and long‐term immune‐suppression are few more serious 
constraints associated with liver transplant [4]. Therefore, it is crucial to look for effective and 
operative alternate approaches of liver transplantation.
Advancements in the field of regenerative medicine open up new horizons and arising 
hope in the treatment of irreversibly damaged liver cirrhosis. Liver regenerative medicine 
mainly emphasizes on the establishment of new therapies to either functionally restore the 
chronically damaged liver tissue or to develop the entire new organ [5]. Elucidation of cel‐
lular and molecular mechanisms during the last couple of decades in the field of hepatic 
organogenesis and regeneration provides milestones in the development of liver regen‐
erative medicine. Moreover, compared to current operative therapies, it is less invasive, is 
less expensive, and avoids the problem of shortage of donors, immune rejection, and other 
similar complications. Ideally, liver regenerative medicine seems an ultimate solution for 
liver cirrhosis.
Liver regenerative medicine uses two key approaches based on cell therapy and tissue/organ 
engineering. Cell‐based therapy is defined as the transplantation of cells from different sources 
with or without differentiation to improve liver function [6]. Transplantation of mature hepa‐
tocytes and liver stem/progenitor cells (LSPCs) from allogeneic sources is already in clinical 
trials. However, current research is intended to overcome the problem of immune rejection 
associated with allogeneic sources and focuses on therapies based on generation of autolo‐
gous hepatocytes from MSCs and induced pluripotent stem cells (iPSCs) [5]. Elucidation of 
cell type, which can be successfully differentiated into functional and transplantable hepato‐
cytes or liver progenitor cells, is another major task under study [7]. Furthermore, researchers 
are trying to refine protocols for proliferation, differentiation, and storage of these cells to 
have them in plenty and always ready to be transplanted.
Second strategy mainly covers the area of liver tissue/organ engineering, engraftment, and 
monitoring in patients. Ongoing therapeutic approaches in tissue engineering include implant‐
able constructs of hepatic tissues and whole organ. For the construction of hepatic tissues, nat‐
ural and synthetic bioactive scaffolds are designed [5]. Nanotechnology and microchip devices 
are contributing a lot in this lane. Moreover, whole organ engineering is also in great focus to 
escape end‐stage liver diseases. However, determination of ideal cell types, cell volume, and 
optimal seeding techniques is yet to be discovered [8, 9].
This chapter deals with the scope of liver regenerative medicine in the treatment of liver cir‐
rhosis. Different operative and proposed therapies along with their pros and cons are the 
major focus of this section and are reviewed in detail.
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2. Hepatic organogenesis
Zygote is the only totipotent structure that leads to the development of blastocyst. Blastocyst 
carries both embryonic and extraembryonic (inner cell mass) cell population. Inner cell mass 
(ICM) forms three germ layers: exoderm, mesoderm, and endoderm. Embryonic liver develops 
from the endodermal layer during ventral foregut closure in the midgut [10]. Cells residing in 
the hepatic bud are bipotent and are called hepatoblasts. Hepatoblasts are columnar in shape, 
release α‐fetoprotein, and differentiate into mature hepatocytes and cholangiocytes [11].
Wingless type (wnt) signaling pathway, together with activin‐A, plays a crucial role in the 
establishment of endoderm during primitive streak formation and differentiation of liver 
precursor cells toward hepatoblasts [12, 13]. Other key factors involved in hepatic fate deter‐
mination are fibroblast growth factors (FGFs) released from cardiac mesoderm and bone mor‐
phogenetic proteins (BMPs) released by septum transversum mesenchyme [3]. Furthermore, 
oncostatin M and hepatocyte growth factor (HGF) control the differentiation of hepatoblasts 
toward hepatocytes [14], whereas Jagged‐Notch signaling pathway is responsible for the 
development of cholangiocytes [15].
Gradually, as the liver development proceeds toward the final stages of maturation, hep‐
atoblast number reduces markedly. Liver becomes populated with mature and unipotent 
hepatocytes and cholangiocytes. The remainder resident cells of liver, that is, Kupffer cells, 
stellate cells, and endothelium, are mesodermal in origin. Majority of the liver functions 
are performed by hepatocytes. On the onset of any hepatic insult, adult liver cells undergo 
apoptosis that calls for the replacement of lost cells or in other words liver regeneration. 
The schematic diagram of liver organogenesis from endodermal layer along with important 
molecular signaling pathways involved in activation or suppression of each step has been 
represented in Figure 1.
Figure 1. Schematic diagram of liver organogenesis. Molecular signals involved in the activation of each stage are 
indicated in the boxes occuring at various steps of liver organogenesis.
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3. Liver regeneration
Elucidation of the cellular and molecular mechanisms involved in liver regeneration provides 
vital scientific grounds for liver regenerative medicine. Depending upon the origin of liver 
damage, different kinds of repair mechanisms are operative [16]. Various surgical and toxin‐
mediated injury models for liver regeneration have been established so far. One of the estab‐
lished and utterly studied model of regeneration is rodent partial hepatectomy [17]. In partial 
hepatectomy model, liver can regenerate to its normal size in 3–10 days even if two‐thirds of 
its mass is surgically removed. A fine coordination of cellular and molecular events occurs 
in the regeneration process of partial hepatectomy. Robust hepatocyte replication followed 
by hypertrophy has been revealed as an underlying cellular mechanism in partial hepatec‐
tomy recovery. This vigorous change in hepatocytes is also accompanied by alteration of gene 
expression patterns, instigation of transcription factors, and release of growth signals. More 
than 100 genes are activated in an early response manner. At least 40% of these early response 
genes are activated by interleukin‐6 (IL‐6) signaling which itself is activated by tumor necrosis 
factor‐α (TNF‐α)‐mediated NFκB (nuclear factor kappa‐B) activation [18, 19]. The recovery of 
liver mass and function of living donor and recipient of liver transplantation in humans seems 
to adopt a similar track.
Besides utilizing mature hepatocytes for liver regeneration, another likely approach is the 
use of liver progenitor cells (LSPCs). They are capable of converting into different cell lines 
found in liver, that is, hepatocytes, oval cells, and stellate cells [20]. LSPCs got experimen‐
tal and clinical support when they were overproliferated in case of induced liver injury by 
acetaminophen and slowly proliferated in case of liver cirrhosis [21, 22]. At present, the main 
focus is on the regenerative capacity of LSPCs when hepatocytes run out of their regenerative 
potential. LSPCs are also proved potential progenitor cells of biliary epithelium in vitro, but 
no specific LSPC markers are identified as yet. It seems that LSPCs are driven by the activation 
of certain genes and the combination of growth factors. Crucially important genes include 
Leucine‐rich repeat‐containing G‐protein‐coupled receptor 5 (LGR5) and the cytokine tumor 
necrosis factor‐like weak inducer of apoptosis (TWEAK), a member of the tumor necrosis fac‐
tor (TNF) superfamily [23]. Some other mitogenic factors also play a crucial role, for example, 
HGF, epidermal growth factor (EGF), TGF‐α, and fibroblast growth factors 1 and 2 (FGF1 and 
FGF2) [24]. However, there is lack of evidence pertaining to in vivo differentiation of LSPCs 
into hepatocytes. The articles published in 2014 used different methodologies to trace the fate 
of liver progenitor cells. They utterly rejected the concept of regenerative capability of LSPCs 
into hepatocytes. Besides, despite lack of proof of the in vivo hepatogenic differentiation of 
LSPCs, they surely can give rise to hepatocyte‐like cells in vitro [20]. Research in this arena is 
ongoing and there is a probability that even in mice a part for oval cells/LSPCs in regeneration 
will be found.
Third major concept in liver regeneration is through extrahepatic cells that is hematopoi‐
etic stem cells (HSCs) and mesenchymal stem cells (MSCs) derived from bone marrow. HSC 
and MSC from bone marrow reach the liver via blood circulation. These HSCs and MSCs 
can populate the liver after hepatogenic differentiation [25]. It is proposed that these bone 
marrow‐derived stem cells are not directly converted into hepatocytes rather they first mix 
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with resident liver cells and then participate in liver repopulation [26]. It has also been sug‐
gested that MSCs with multilineage differentiation potential provide a great variety of cells 
for nonhematopoietic tissues like liver tissues [27]. Though they are highly heterogeneous in 
nature, only a little fraction of it contributes to liver regeneration [28]. It is notable that bone 
marrow cells take part in the regeneration of liver endothelium. Twenty percent of the liver 
endothelial cells are made by the bone marrow‐derived endothelial cells [29]. There is a need 
of concerning involvement of bone marrow‐derived stem cells in liver parenchyma regenera‐
tion, for designing the methods for cellular therapy of liver disease [16].
4. Cell‐based therapies for regeneration of liver cirrhosis
Cell‐based therapies are the oldest and most efficient method to regenerate damaged liver. 
Effective engraftment and proliferation of donor cells in the recipient liver are the main issues 
of concern for liver regeneration through cell‐based therapy. Depending on the donor source, 
cells can be of autologous [30], allogeneic, or syngeneic nature [31]. The cells are injected into 
the recipient through portal vein, peripheral vein [30], and intraspleenic [32] or intraperi‐
toneal route. To enhance the transplantation efficiency, conditioning of recipient liver with 
partial hepatectomy [33, 34], liver irradiation [35, 36], or portal embolization [37] has been 
recently proposed. Broadly, cells are categorized into two main categories; stem cells and 
mature hepatocytes are the potential cell‐based therapies adapted to date in the cure and 
regeneration of liver cirrhosis [5]. The roles of these cell‐based therapies are shown in Figure 2 
and are discussed one by one in detail in the following section.
4.1. Hepatocytes and liver regeneration
Liver is chiefly composed of hepatocytes. Hepatocyte proliferation plays a distinctive role in 
liver regeneration under both acute and chronic injury conditions. The unique characteristic 
Figure 2. Different types of cells and their mode of application for cell‐based therapies of liver cirrhosis. Different types 
of cells isolated from humans and being used in liver regeneration are shown on the left side of the figure. Each of the 
cell type has been injected and has recovered liver functions either through only in vitro proliferation (hepatocytes), via 
differentiation toward hepatocytes (ESCs and iPSCs) or through both (MSCs, LSPCs).
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of hepatocytes to proliferate under stress conditions makes them ideal cell type for cell‐based 
therapies. Primary hepatocytes were the very first type of cells to be used for cell‐based ther‐
apy of liver. Isolated hepatocytes are infused either directly into the liver or into the spleen 
from where they can migrate to and settle down in the liver. The hepatocyte transplantation 
has shown to considerably improve the hepatic functions even in end‐stage liver failure [38]. 
Typically, hepatocytes are harvested from the livers that are not suitable for transplantation 
[39]. However, due to problem of immune rejection, it was also tried to isolate hepatocyte 
from patient’s biopsies [40].
Although primary hepatocytes are ideal for use in liver regeneration, this approach is prone 
to certain limiting factors. Inadequate supply of the required cells, slow in vitro prolifera‐
tion rate [18], dedifferentiation within 72 hours of culturing [41], susceptibility to freeze‐thaw 
damage, and loss of certain characteristic features in culture conditions are major obstacles 
that hinder the utilization of these cells for liver regeneration [38]. The isolated primary 
hepatocytes are of low quantitative value, and an autologous isolation of this cell population 
involves patients’ inconvenience. Typically, hepatocytes are harvested from the livers that are 
not suitable for transplantation, so the quantitative and qualitative values of obtained cells 
vary considerably. All of these constraints have played a pivotal role in shifting focus toward 
alternate cell‐based therapies.
4.2. Stem cells in liver regeneration
With the therapeutic focus being set on the establishment of personalized medicine and the 
replacement or regeneration of damaged tissue, stem cell‐based therapies may provide a 
strong platform. The properties of indefinite cell division and differentiation potential into 
other cell types make the stem cells an ideal choice for cure and regeneration of liver cirrhosis. 
Another important property of stem cells is their ability to create and provide a favorable 
environment for growth of primary hepatocytes and/or hepatocyte‐like cells [5]. Coculturing 
MSCs with primary hepatocytes results in their improved viability and function by provid‐
ing structural and paracrine trophic support [41–43]. Moreover, stem cell therapy holds great 
potential especially in the cure of inherited liver diseases, where, together with gene therapy, it 
may correct metabolic disorders permanently without even using immunosuppressive drugs 
[5]. Chiefly, two approaches of stem cell‐based liver regeneration are in practice either their 
direct injection or in vitro differentiation toward hepatocyte‐like cells and transplantation.
Some types of stem cells show efficient growth in vitro, could be a rich pool to supply hepa‐
tocytes/precursor cells, and thus be used largely for transplantation. If the wide availability of 
human hepatocytes is made possible, this could be a major breakthrough in the treatment of 
various liver diseases. However, the research work debating good capacity stem cell therapy 
lack in reproducibility evidence or some of these even have been overoptimistically inter‐
preted. Another important milestone is to decide on the preference of stem and precursor cell 
types. It is a difficult task to compare different cell types with respect to their reported capac‐
ity of differentiation toward hepatocytes [44]. We therefore discuss the possibilities these cell 
therapies offer one by one, along with the limitations which are making these feats harder to 
achieve.
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4.2.1. Embryonic stem cells and hepatocyte generation
Differentiation of cultured embryonic stem cells toward hepatocyte‐like cells in vitro appears 
to be the most studied model of mature hepatocyte generation. In mouse models of liver 
injury, hepatocyte‐like cells not only recover the liver by proliferation but also provide trophic 
factors that assist the endogenous hepatic regenerative capability [45]. Human ESCs efficiently 
form embryoid bodies in suspension cultures forming three germ layers [46]. Hepatocyte iso‐
lation from this heterogeneous cell population is very difficult, suggesting endoderm enrich‐
ment to be a practical option with maximum hepatocyte yield.
A directional differentiation strategy for the generation of functional hepatocytes from 
embryonic stem cells involves sequential supplementation of various molecular factors 
(growth factors and cytokines necessary for development of human embryonic liver)‐
enriched growth medium. The molecular factors involved in early embryonic differentiation 
such as fibroblast growth factor (FGF2/4), bone morphogenetic protein (BMP2/4), activin A 
and Wnt3 can be used for endoderm enrichment from cultivated embryoid bodies [44, 46]. 
FGF2/4 stimulates the development of hepatoblasts from cultured ESCs and the generation 
of mature hepatocytes, whereas HGF plays a supportive role in hepatocyte generation from 
hepatoblasts. Dexamethasone (glucocorticoid hormone) induces the production of adult 
hepatocyte‐specific proteins. This strategy ensures an 80–90% hepatocyte yield. Recently, 
Wang et al. established a polymer‐modified nanoparticle‐based sustained delivery system 
for growth factors to direct stem cell differentiation into hepatocytes [47]. Their approach can 
help to overcome the limitations linked with current models and make sure efficient delivery 
of growth factors to improve ESC differentiation toward a hepatocyte‐like lineage.
The final and most important step in this strategy involves isolation of absolute hepatocyte 
population from a heterogeneous mixture containing other hepatic precursors and immature 
hepatocytes. Basma et al. used asialoglycoprotein receptor ASGPR1 (hepatocyte‐specific cell 
surface marker) expression based sorting to enrich the pure hepatocyte populations [48]. To 
enhance the isolation efficiency of hepatocytes based on ASGPR1, fluorescent‐labeled or mag‐
net‐coated antibodies are further proposed [49]. However, further research is required to be 
performed to isolate definitive hepatocyte population or to obtain a relatively absolute ratio 
of hepatocytes from ESCs [50].
Despite their success stories, there are a number of ethical issues concerning the use of human 
ESCs in liver regenerative medicine [50]. Furthermore, pluripotency of these cells is very dif‐
ficult to handle leading to an uncontrolled regenerative potential. Above all, putative tumori‐
genicity associated with transplantation of ESCs proves to be an additional barrier for their 
clinical application [49–50].
4.2.2. Bone marrow stem cells (BMSCs)
In bone marrow, three different pluripotent cell populations, that is hematopoietic stem cells 
(HSCs), MSCs, and multipotent adult progenitor cells (MAPCs)/endothelial progenitor cells 
(EPCs), are present [51]. Peripheral blood, umbilical cord blood, and synovial fluid are addi‐
tional sources of HSCs and MSCs. HSCs and MSCs can be advantageous cell sources for liver 
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regeneration as compared to hepatocytes since they can be obtained relatively easily from 
blood and bone marrow of live donors. Since BMSCs are immune‐modulators, a reduced 
chance of graft rejection is an additional property of these stem cells [47, 51]. In clinical trials, 
patients with autologous BMSC (CD34+ cell) transplantation had no procedure‐related com‐
plications and showed improved quality of life [30]. MSCs have proven reliable for treatment 
of liver cirrhosis in phase I and phase II clinical trials as shown in Table 1.
Cell source Liver cirrhosis No. of 
patients
Administration 
route
Follow‐up 
period
Outcomes/clinical 
significance
References
Hepatocytes 
(autologous)
Liver cirrhosis 9 intraportal 10 months 
in only one 
patient
Longer survival [40]
EpCAM+ Fetal 
liver‐SCs
Advanced 
cirrhosis
2 hepatic artery 12 months Biochemical 
and clinical 
improvement
[74]
End‐stage liver 
cirrhosis
25 hepatic artery 6 months Improved liver 
function and 
MELD score
[32]
BM‐MSCs Decompensated 
liver cirrhosis
4 peripheral vein 12 months Well‐tolerated and 
safe procedure; 
improved liver 
function
[75]
post‐HCV liver 
cirrhosis
20 intrasplenic 6 months Decreased TBIL, 
AST, ALT, PT; 
improved ALB, 
PC, PT, INR
[76]
Autologous 
BM‐MSCs
Alcoholic 
cirrhosis
11 hepatic artery 12 months No significant 
side effects; 
histological 
improvement; 
improved CP 
score
[77]
Liver cirrhosis 9 peripheral vein 6 months No major adverse 
effects; improved 
ALB, CP scores
[78]
BM‐MSCs 
(Differentiated vs 
undifferentiated)
post‐HCV liver 
cirrhosis
10: control 
15: treated
intravenous 6 months Improved MELD 
score, BIL, ALB, 
and PC
[79]
UC‐MSCs Primary biliary 
cirrhosis
7 peripheral vein 12 months No obvious side 
effects; decreased 
serum ALP and 
GGT
[80]
Post‐HBV 
decompensated 
liver cirrhosis
15: control 
30: treated
intravenous 12 months No significant 
side effects; 
improved liver 
function and 
MELD score; 
reduced ascites
[81]
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Hematopoietic stem cells originating from bone marrow are efficient stem cell population that 
migrates to the site of injury and participate in the repopulation of damaged tissue. In liver 
regeneration, this stem cell population is postulated to contribute based on the cell fusion capa‐
bility of the BMSCs [52, 53] rather than cellular differentiation. In murine hepatectomy models, 
BMSCs were found to fuse with hepatocytes, and the resultant hybrid cells were shown to be 
responsible for triggering proficient liver regenerative reaction [54]. Therapeutic mechanisms 
of MSCs are reported to be more clear as compared to those of HSCs. MSCs not only reduce 
Cell source Liver cirrhosis No. of 
patients
Administration 
route
Follow‐up 
period
Outcomes/clinical 
significance
References
Autologous MSCs 
from iliac crest
Decompensated 
cirrhosis
12: control 
15: treated
peripheral vein 12 months No beneficial 
effect
[82]
End‐stage liver 
disease
8 peripheral or 
portal vein
6 months No adverse 
effects; improved 
MELD and liver 
function
[83]
Allogenic MSCs Autoimmune 
disease‐induced 
liver cirrhosis
26 peripheral vein 24 months No obvious side 
effects; improved 
MELD and liver 
function
[84]
G‐CSF 
mobilization of 
CD 34+ BMSCs
Severe liver 
cirrhosis
40: controls 
8: treated
subcutaneous 8 months No adverse 
events; improved 
MELD score
[85]
Alcoholic 
cirrhosis
11: control 
13: treated
subcutaneous 3 months Effective CD34+ 
cells mobilization; 
increased 
HGF; induced 
hepatocyte 
proliferation
[86]
Liver cirrhosis 18 subcutaneous 3 weeks No severe 
adverse events; 
no liver function 
significant 
modification
[87]
Autologous G‐
CSF‐mobilized 
cultured CD34+ 
BMSCs
Alcoholic liver 
cirrhosis
9 hepatic artery 3 months No side effects; 
improved BIL, 
ALT, AST, CP 
score and ascites
[88]
PBMCs from G‐
CSF mobilized PB
Decompensated 
liver cirrhosis
20: control 
20: treated
6 months No major adverse 
effects; improved 
liver function
[89]
EpCAM: Epithelial cell adhesion molecule; GGT: γ‐glutamyl transferase; ALT: Alanine aminotransferase; TBIL: Total 
bilirubin; AST: Aspartate aminotransferase; CP: Child‐Pugh; HGF: Hepatocyte growth factor; HCV: Hepatitis C virus; 
PT: Prothrombin time; ALB; Albumin; PC: Platelet count; INR: International normalized ratio; MELD: Model for end‐
stage liver diseases; ALP: Alkaline phosphatase; UC‐MSC: Umbilical cord blood‐mesenchymal stem cells; G‐CSF: 
Granulocyte‐colony‐stimulating factor; BM‐MSCs: Bone marrow‐mesenchymal stem cells.
Table 1. Clinical trials of cell‐based therapies along with their route of administration, follow‐up, and outcomes.
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inflammation and fibrosis but they also increase liver regenerative response in a much rapid 
manner than HSCs [55]. CD34 is reported to be an efficient cellular marker for the isolation of 
HSCs [30]. However, these cells have showed profibrogenic potential in some cases [56].
Despite wide use in preclinical setting and clinical trials, the BMSCs have to be evaluated 
extensively for their potential role in liver regeneration before being applied to the wide clin‐
ical utilization. Tumorigenicity of MSCs is another constraint that needs to be considered 
while using this stem cell population in clinical application [57].
4.2.3. Adipose‐derived stem cells (ADSCs)
Adipose tissue is another source of MSCs used for hepatic regeneration. ADSCs seem to be 
pluripotent and have the potential to differentiate into cells of multiple germ lines such as 
bone, nerve, heart, and adipose tissue. These cells are advantageous over BMSCs because 
of their higher in vitro proliferation activity and differentiation potential [58]. The sufficient 
availability of adipose tissue from most patients with no substantial defects renders ADSCs an 
efficient alternative source of stem cells for liver regeneration [59]. Differentiation of ADSCs 
into functional hepatocytes involves activation of Wnt/beta‐catenin signaling through glyco‐
gen synthase kinase 3 inhibitors [60]. Further research is needed to evaluate the potential of 
this stem cell lineage in liver regenerative setups.
4.2.4. Liver stem/progenitor cells (LSPCs)
Hepatoblasts being bipotent are capable of self‐renewal and differentiation into cholangio‐
cytes and hepatocytes. In contrast to ESCs and MSCs, both of which need to go through 
sequential differentiation to develop into mature hepatocytes, LSPCs have a destined fate. 
Hence, they carry significant potential to be used in liver regenerative medicine. LSPCs can 
undergo several rounds of proliferation. These cells have the potential to differentiate into 
hepatic and biliary cell lineages and to repair the damaged liver tissue [50, 61]. LSPCs are 
thought to be the cells that do not contribute to the routine liver yields. Instead, they appear 
in advance stages of liver injury such as primary biliary cirrhosis and nonalcoholic cirrhosis 
[21]. Many properties of embryonic hepatoblasts are shared by LSPCs. Certain surface mark‐
ers help in selective isolation of LSPCs via immune selection. They express epithelial cell 
adhesion molecules (EpCAM) and have been isolated against this surface marker [11] from 
fetal as well as adult human liver [62]. Differentiation of EpCAM‐positive cells can yield both 
hepatocytes and cholangiocytes [63, 64]. Clinical trials of EpCAM‐positive LSPCs are given 
in Table 1.
LSPCs, on the other hand, have certain limitations which hinder their application in liver regen‐
erative medicine. First of all, these cells are present in a very small quantity in the adult human 
liver making it unproductive to isolate them on the basis of their markers. Our research group 
had addressed this problem in a recently published study, where BMSCs were differentiated 
toward oval cell‐like cells. These oval cell‐like cells were comparable to control oval cells in 
their efficiency to reduce liver injury [65]. Another major issue associated with LSPCs is their 
great potential to induce hepatic tumorigenicity. Presently, this is a major limiting factor for 
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their utilization in liver therapeutics and regenerative medicine. Notably, human liver progeni‐
tor cells have been found to be present and contributing in the development of nonalcoholic 
steatohepatitis in pediatric and adult human patients. They are supposed to be playing fibro‐
genic role in such cases as reported by Sobaniec‐Łotowska et al. [66]. Comprehensive research 
at preclinical level is required to probe into these issues properly to understand the appropri‐
ateness of these cells for clinical trials.
4.2.5. Induced pluripotent stem cells (iPSCs)
The establishment of iPSCs by reprogramming somatic cells through certain transcription 
factors (Oct‐3/4, Sox2, Nanog, c‐Myc, Klf‐4) has proven a potential new source of stem cells. 
These cells exhibit properties essential for ESCs and have the potential to differentiate into 
the derivatives of all three germ layers [67]. However, iPSCs avoid the ethical issues related 
to ESCs since no human embryo is used for their production [3]. iPSCs being autologous in 
nature also evade the problem of immune rejection. Although there are unlimited sources for 
iPSCs generation, to ensure a relatively homogeneous hepatocyte culture, the use of hepato‐
cytes or/and other endodermal cells is recommended. It can play an important role as cells 
carry an “epigenetic memory” allowing the iPSCs to differentiate toward cells of definitive 
germ layer [68].
Permanent retroviral integration, a process which was initially used by Takashi and cowork‐
ers in 2007 [69] is one of the earliest methods used for iPSCs production. With advancement 
in the field, it is possible to generate iPSCs without using retroviral transfection. Nowadays, 
a number of methods such as excisable viral transfection [70], microRNA transfection [71], 
episomal plasmid transfection [72], and mRNA transfection [73] are being harnessed for the 
production of functionally efficient iPSCs. Once generated, iPSCs can be directed to differen‐
tiate toward definitive endoderm which will differentiate into hepatoblasts and finally into 
hepatocytes in a sequential manner involving various growth factors, cytokines, and signal‐
ing pathways as described previously in this chapter. The resultant hepatocyte‐like cells are 
more like fetal hepatocytes rather than mature hepatocytes, a phenomenon shared by all the 
stem cell‐generated hepatocytes [3]. Although an efficient source of autologous transplanta‐
tion, iPSCs‐derived hepatocytes have certain shortcomings as well.
5. Tissue engineering and liver cirrhosis
Cell‐based therapies have shown promising results in the improvement of liver cirrhosis. 
However, inefficient engraftment of cells due to surrounding conditions of diseased liver 
results in variable outcomes [3]. Tissue engineering, a recent advancement in liver regen‐
erative medicine, is dedicated in deriving the ways to escape the problems associated with 
direct cell‐based therapies. It mainly focuses on the development of biocompatible scaffolds 
and extracorporeal liver devices suitable for either in vitro or in vivo applications. Schematic 
representation of key approaches used for liver tissue engineering is shown in Figure 3 and 
discussed in detail with their merits and relevant complications in the following section.
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5.1. Generation of bioactive scaffolds
Bioactive scaffolds are those that have the ability to elicit cell growth and differentiation. 
In modern tissue engineering, bioactive scaffolds are so much advantageous as they mimic 
the natural ECM environment of the liver. One of the major components of these scaffolds 
is a structural protein collagen normally found in skin, bone, and cartilage [90]. Collagen 
highly supports attachment, proliferation, differentiation, growth, and migration of cells. 
Further, collagen‐based bioscaffolds have shown in vitro differentiation of embryoid bod‐
ies derived from embryonic stem cell into hepatocyte‐like cells [91, 92]. Hyaluronic acid is 
another important component of the extracellular matrix. It is involved in the regulation of 
cell proliferation and expansion. The immature and mature hepatocytes of fetal and adult 
liver cells express surface receptors for hyaluronic acid, that is CD44 [93]. By utilizing this 
property of hepatocytes, hydrogels consisting of hyaluronic acid and its derivatives are syn‐
thesized possessing more adhesive power for hepatocytes. They can retain viability of hepa‐
tocytes for 4 weeks [93].
Other natural biomaterials being utilized in the formation of bioactive scaffolds are alginate, 
chitin, chitosan, silk, matrigel, and sponge. Its best example is silk‐fibroin‐based microfluidic 
devices that successfully supported the growth and differentiation of HepG2 cells [94]. Hepatic 
Figure 3. Schematic diagram of liver tissue engineering. Solid lines show the approaches already ongoing whereas 
dotted lines indicate the proposed mechanisms.
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organoids and smaller parts of tissues can be grown from porcine hepatocytes on the matrix, 
consisting of albumin and chitosan (a deacetylated form of chitin) [95]. Scaffold containing chi‐
tosan nanofibers associated with the glucose residues showed prolonged metabolic activity of 
cluster of cells originated from hepatocytes [96]. Hydrogels formed by the natural biomaterials 
such as alginate and matrigels are more biocompatible and improve the seeding potency of 
hepatocytes. The basal membranes of murine chondrosarcoma are used for extraction of pro‐
teins (laminin, heparan sulfate proteoglycan, collagen type IV) that are used in the formation of 
matrigels. Hepatocytes initially started to grow in scaffolds containing matrigels into shapeless 
clusters of cells followed by their implantation in natural organ [97].
However, it has not yet been recognized that which composition would provide the best 
physicochemical characteristics for defined growth pattern of hepatocytes. Moreover, due to 
xenogeneic and tumorigenic origin of matrigels, they are not considered good for tissue engi‐
neering of liver. Although utilization of natural polymers in three‐dimensional (3D) scaffolds 
creates some histoarchitectural features that help a lot in the generation of cell‐to‐cell and 
cell‐to‐matrix interactions, uncontrollable physicochemical properties, degradability, lack of 
regenerative ability, and inconsistent mechanical properties halt its clinical implication.
5.2. Synthetic polymers used in liver tissue engineering
In comparison to natural biomaterials used in tissue engineering, synthetic materials pro‐
vide a wide range of properties and a better control over them. Their biocompatibility and 
biodegradability can be tuned easily. Scaffolds containing biodegradable polymers facilitate 
regeneration, transplantation, and degradation of cells on time. Commonly used biodegrad‐
able polymers are polylactic acid, polyglycolic acid, polyanhydrides, polyfumarates, polyor‐
thoesters, polycaprolactones, poly‐ L–lactic acid, and polycarbonates [98].
A synthetic chemical polyglycolate–polylactate used in 3D scaffolds can turn fetal hepato‐
blasts to mature hepatocytes [99–101]. The main limitations of polyglycolate–polylactate are 
chemical unpredictability, surface corrosion, and hydrophobicity [102]. However, chemical 
instability of poly (alpha‐hydroxy) acids results in the formation of hydrolysis products, 
which can induce inflammatory responses. The chemical modification of polymers (e.g. the 
incorporation of proteins and special bioactive domains) increases the biocompatibility of bio‐
engineered matrices and improves scaffold adhesion properties stimulating cell attachment 
and migration, thereby, facilitating liver tissue repair [103]. 3D hepatocyte cultures can also 
be grown successfully in polyurethanes. Polyurethane foams are used to grow hepatocytes 
and hepatocyte‐like cells in bioreactors. Highly functional multicellular structures are formed 
within the pores of these polyurethane foams [104]. Because of these characteristic polyure‐
thane foams are widely used in 3D scaffolds for the production of bioartificial liver [105].
5.3. Implementation of nanotechnology and microchip devices in tissue engineering
Nanotechnology and microchip devices have tremendous use in liver tissue engineering. 
Microfluidic devices containing very small volumes of cells, effector molecules, ECM, and so on 
are used to produce natural biochemical environment around the cells so that they may behave 
as they do in natural organ [106]. Using the microbioreactors, microcapsule fabrication is done 
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that leads to the encapsulation of hepatic cells and their precursors. In these special kinds of 
bioreactors, the regular supply of oxygen, water, and nutrients is ensured and metabolic wastes 
are eliminated. These capsules are made of polydimethylsiloxane and its derivatives because 
they are highly permeable to water. The polydimethylsiloxane capsules and microspheres of 
alginate have showed efficient growth of encapsulated hepatocytes that were seeded on them 
due to its radical perfusion properties. Due to its remarkable properties, polydimethylsiloxane 
is a promising tool for bioartificial liver system [72].
To estimate cytotoxic effects of drugs on liver cells, 3D microfluidic cell panels have also been 
introduced. These panels create the natural environment for cells as they are made up of porous 
hydrogels and are lined with hepatocytes. These pores are taken as capillaries by the cells. 
Various pharmacokinetic models are being studied with the help of these panels [107, 108].
Speaking collectively, complex microarchitecture of liver tissues having proper cell to cell 
interactions and supply of cells with oxygen and nutrients are produced from biologically 
produced microorgans of liver. These microorgans are produced ultimately from bioactive 
microscaffolds; 3D hepatocyte panels [109].
5.4. Organ‐based regeneration of liver
The development of whole organ using different techniques in tissue engineering is remark‐
able and this decreases the problems related to shortage of donor organs for transplant and 
immunosuppression. In order to build a functional liver organ, the first and foremost needed 
is a scaffold. Among many of the trialed materials for scaffolds, porcine/murine‐based scaf‐
folds have proved better. Second, what is needed is the presence of extracellular matrix in the 
scaffolds to provide the hepatocytes with their niche for their optimal growth and regulation 
of cellular behaviors [110, 111].
Complete decellularization of native organ is achieved via detergent perfusion for 24–48 
hours, in order to get a xenogeneic scaffold. A point that must be mentioned while decellu‐
larization is: ECM should not be damaged and it should have under 50 ng double‐stranded 
DNA/mg of ECM to avoid immune rejection [112]. After decellularization, recellularization of 
xenogenic scaffold with highly functional hepatocytes is done. These cells are obtained either 
from deceased donor grafts or from partial hepatectomy. However, it is difficult to obtain 
an appropriate volume of cells. The adult hepatocytes are not considered good for organ 
regeneration because they show poor in vitro proliferation. Fetal liver cells show high in vitro 
rate of proliferation but they are not easy to obtain. The human‐derived cell lines that show 
exponential growth in vitro also cannot be used for implantable organs as they pose the threat 
of metastasis [113, 114]. Porcine hepatocytes remained successful in BAL system but due to 
immunogenic rejection they cannot be used for organ bioengineering [5]. Human‐derived 
autologous stem cells, that is iPSCs, are capable of producing liver‐specific proteins but they 
produce the albumin at a lower rate than in adult human liver so they are also not a good 
choice. However, human bone marrow cells are showing promising results in vitro, though 
they are not yet tested clinically [115].
The recellularization of scaffolds fitted in the tissue cultures of organ chambers is done 
either by direct parenchymal injections or by single or multistep perfusion in physiological 
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 pressure. As a proof of whole liver decellularization and recellularization concept a rat model 
was utilized for the proliferation of adult rat hepatocytes. Proliferation was confirmed by 
different markers. Ninety percent of hepatectomized rat models that were given spheroid 
tissue‐engineered liver showed an increased survival period from 16 to 72 hours. But to their 
dismay, the rats died of the small‐for‐size syndrome [116, 117].
Besides facing problem in the selection of most suitable cell lines, another hurdle is to develop 
a vascular network for the support of cell aggregates [118]. Organ bioengineering offers a 
hopeful way to get out of complications associated with liver cirrhosis. The best scaffold onto 
which organ is tissue engineered is a decellularized xenogenic scaffold having intact network 
of ECM. Studies are being focused on the determination of ideal cell types for humans. Deep 
research is also going on to find the optimal cell seeding techniques and cell volume required 
to sustain necessary functions [5].
6. Conclusion
In conclusion, the field of regenerative medicine has taken a successful initiative toward the 
ultimate solution of end‐stage liver diseases. Particularly, the dynamism of various cell‐based 
therapies has arisen much hope and facilitated the development of more challenging tissue 
engineering. Initially, tissue engineering focused on the use of natural and synthetic scaffolds 
to grow hepatocytes and develop liver tissues. Currently, much work is ongoing to create 
liver microorgans to organoids. Crucial aim of future research is to construct whole bioengi‐
neered liver. In this regard, the use of decellularized livers has been proposed to create liver 
organoids leading to the construction of whole bioengineered liver. However, organ bioen‐
gineering faces the problems of selection of suitable cell type and appropriate development 
of a vascular network, which will support cell aggregates. Major challenges associated are 
the determination of suitable cell type, optimal cell volume, and seeding techniques required 
to endure essential hepatic functions. The current scenario propels to conduct much more 
experimental work to successfully construct whole bioengineered liver and its effective clini‐
cal applications to replace liver transplantation.
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